MORE►
cancer
UT Southwestern's Clements University Hospital [Photo: UTSW]
CPRIT Approves Over $16M in Cancer-Fighting Grants to Dallas-Area Institutions
by Lance Murray | Feb 27, 2024
Included in the 12 Dallas-area funding awards is a $4 million Rising Star grant to bring Stefan Gloeggler, Ph.D., to UT Southwestern Medical Center from the Max Planck Institute of Multidisciplinary Sciences in Göttingen, Germany.
by Lance Murray |
Feb 22, 2024
Carson Leslie Foundation, Grant Halliburton Team Up to Support Kids With Cancer—And Deliver Smiles
MORE►
by Lance Murray |
Dec 6, 2023
UT Arlington principal investigator Dr. Suvra Pal said that previous studies modeling the probability of a cancer cure—also called the cure rate—"used a generalized linear model." The new statistical modeling method published by Pal and his student is said to be 30% more effective in predicting who will be cured of cancer and who will need further treatment.
MORE►
by David Seeley |
Sep 18, 2023
The award will help SMU biology professor Zhihao Wu determine if different "quality control pathways" in our bodies might be working together to repair damaged components in cells. The research could help lead to "new therapeutic targets" for hallmarks known to cause many human diseases, the university said.
MORE►
UT Southwestern Harold C. Simmons Comprehensive Cancer Center [Photo: UTSW]
Simmons Cancer Center Investigators Get Nearly $15M in CPRIT funding
by Lance Murray | Mar 13, 2023
“Our researchers continue to push the envelope on developing a better understanding of cancer and new ways to help cancer patients in Texas and beyond,” said Center Director Carlos L. Arteaga, M.D.
MORE►
by Lance Murray |
Mar 9, 2023
The researchers discovered how healthy bacteria can escape the intestine, travel to lymph nodes and cancerous tumors elsewhere in the body, and boost the effectiveness of certain immunotherapy drugs. “Now we understand that mechanism much better and, in the future, hope to use this knowledge to better fight cancer," said UT Southwestern's Andrew Y. Koh, M.D.
MORE►
by Lance Murray |
Mar 7, 2023
NanOlogy said the new patent covers a method of treating cancer by intratumoral administration of large surface area microparticle taxanes in combination with systemic administration of immune checkpoint inhibitors. “The goal is to identify which combinations can increase the immune response, thereby increasing the overall solid tumor response to treatment," said NanOlogy Chief Medical Officer Gere DiZerega.
MORE►
by Lance Murray |
Mar 2, 2023
Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....
MORE►
McKesson Forms Joint Venture with HCA Healthcare to Fight Cancer
by Kevin Cummings | Jun 23, 2022
Two giants in their industry are teaming up to accelerate cancer research. The new joint venture is an "important step forward" to increase access to clinical trials, says McKesson CEO Brian Tyler, McKesson CEO.
Separate from the joint venture deal, McKesson will acquire Genospace, a personalized precision medicine platform that’s part of HCA’s research institute.
MORE►
by Kevin Cummings |
Jun 2, 2022
Instead of shipping a patient's blood to a lab for customized cell therapy, Lupagen does the procedure "in vivo," using a dialysis-like treatment at the patient's bedside. Now it's collaborating with Umoja Biopharma to use its drug-delivery tech to place targeted immunotherapies in patients.
“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."
“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."
MORE►
by David Seeley |
Aug 16, 2021
Stelfonta received FDA approval last November to treat dogs with non-metastatic, skin-based mast cell tumors (MCTs)—the most common malignant skin tumor in dogs. The injection is now available at vet clinics across the U.S., with an 88% "satisfactory experience" rate to date.
MORE►
by Alex Edwards |
Jun 17, 2021
The investment was led by Advantech Capital, a PE fund based in China that focuses on TMT, pharmaceuticals, and healthcare. This combined with the support from the Cancer Prevention and Research Institute of Texas (CPRIT), which granted OncoNano $9.97 million last year, will support Phase 3 clinical trials for the biotech's technology that can diagnose and treat cancer with high specificity.
MORE►
Panna Sharma, CEO of Lantern Pharma
Dallas’ Lantern Pharma Hits Major Milestone on its AI Platform to Advance its Oncology Drug Research and Development
by Alex Edwards | Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
by Alex Edwards |
Oct 15, 2020
The novel invention from researchers at Texas Woman’s University in Denton could greatly contribute to cancer treatment research. The compounds can prevent the growth of breast, lung, and colon cancer cells.
MORE►
by Lance Murray |
Feb 26, 2020
Using innovative new technologies and targeted therapies, the Dallas biotech startup aims to help patients with cancer, give them hope, and prolong their lives.
MORE►
by Lance Murray |
Dec 12, 2019
The Genomic Profiling Similarity Score uses over 6,500 mathematical models in a machine learning algorithm to compare molecular characteristics of a patient's tumor against Caris' extensive database.
MORE►
